Corticosteroids in Hyperinflammatory Phenotype of Critical Illness
Key facts
- Who runs it
- Bin Du
- Where
- China11 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 150 people, planned
- Started
- 15 Apr 2026
- Expected to end
- 1 Jun 2028
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Methylprednisolone (MP)
- Placebo
- Record updated
- 18 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Age ≥ 18 years
- Onset of ARDS and/or sepsis within 72 hours; ARDS is defined according to the Berlin definition: onset within 1 week of a known clinical insult or new or worsening respiratory symptoms; bilateral opacities on chest imaging not fully explained by pleural effusions, lobar or lung collapse, or nodules; respiratory failure not fully explained by cardiac failure or fluid overload; and PaO2/FiO2 ≤300 mmHg with PEEP ≥ 5 cm H2O; Sepsis is defined according to Sepsis-3 as suspected or confirmed infection accompanied by an acute increase in SOFA score of ≥ 2 points attributable to infection
- Requirement for invasive mechanical ventilation
- Hyperinflammatory phenotype, defined as a predicted probability ≥ 0.50 using the clinical classifier
- Written informed consent provided by the participant or a legally authorised representative
Who cannot take part
- Systemic corticosteroid exposure at a prednisone-equivalent dose > 0.3 mg/kg/day within the 3 weeks preceding randomisation, or use of any immunosuppressive agent within the same period.[16]
- Solid-organ transplantation or allogeneic stem-cell transplantation
- Concurrent participation in another interventional clinical trial
- Severe congenital or acquired immunodeficiency, including HIV infection
- Brain death, expected death within 24 hours, or advanced malignancy or other end-stage disease with a life expectancy of less than 6 months
- Life-threatening active fungal infection or active tuberculosis
- Known hypersensitivity to corticosteroids
- Neuromuscular disease that substantially impairs spontaneous breathing
- Any other clinical condition that, in the opinion of the treating physician or investigator, makes participation inappropriate
- High vasopressor requirement, defined as a norepinephrine-equivalent dose (NEE) ≥ 0.25 μg/kg/min
- A do-not-resuscitate order or a decision to withdraw or withhold life-sustaining treatment
- Pregnancy or lactation
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn whether methylprednisolone improves outcomes in critically ill patients with a hyperinflammatory phenotype. It will also evaluate the safety of methylprednisolone at different doses.
Read full original descriptionShow less
The main questions it aims to answer are:
* Does methylprednisolone improve organ function compared with placebo? * Does methylprednisolone reduce the risk of mortality within 30 days?
Researchers will compare high-dose methylprednisolone (160mg/d), low-dose methylprednisolone (80mg/d), and placebo (normal saline) to evaluate effectiveness and safety.
Participants will:
* Receive high-dose methylprednisolone, low-dose methylprednisolone, or placebo every 12 hours for the first 3 days * Be reassessed on Day 4 based on their inflammatory status If the hyperinflammatory phenotype persists, the treatment dose will be reduced by half and continued until Day 7 or ICU discharge, whichever occurs first If the patient transitions to a hypoinflammatory phenotype, the study treatment will be discontinued * Be monitored daily in the intensive care unit for organ function, inflammatory status, and need for organ support * Be followed for up to 30 days after randomization to assess survival and recovery
The 3 groups in the trial
- high dose methylprednisolone groupTreatment being tested
Methylprednisolone 80 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 40 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.
Treatment: Methylprednisolone (MP)
- low dose methylprednisolone groupTreatment being tested
Methylprednisolone 40 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 20 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.
Treatment: Methylprednisolone (MP)
- placebo groupPlacebo, for comparison
Normal saline (100 mL) will be administered intravenously every 12 hours for the first 3 days. On day 4, patients will be reassessed prior to dosing; if the hyperinflammatory phenotype persists, normal saline (100 mL) will continue to be administered every 12 hours until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy, Safety, and Tolerability of Methylprednisolone in Critically Ill Patients With the Hyperinflammatory Phenotype: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Trial
- Record updated
- 18 November 2026